Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Editorial
Nature Biotechnology 26, 476 (1 May 2008) | doi:10.1038/nbt0508-476
Nothing to see here
Abstract
The Journal of the American Medical Association (JAMA) played a considerable part in manufacturing media outrage last month over an article 'revealing' Merck's use of ghostwriters and rubber stamp experts in the preparation of clinical research articles on Vioxx (rofecoxib). Although the JAMA article (299, 1800–1812, 2008) revealed nothing new about the ghostwriting practice and so-called 'guest' authorship, the JAMA editors nevertheless felt moved to introduce a new, stricter set of policies on authorship and conflicts of interest.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
